Brief: AstraZeneca Says Enhertu Improved PFS In 1L HER2m Lung Cancer
17/08/2026 07:33
BRIEF-AstraZeneca Says Enhertu Improved PFS In 1L HER2m Lung Cancer Aug 17 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA PLC - ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER
ASTRAZENECA - ENHERTU FIRST HER2-DIRECTED MEDICINE TO IMPROVE PFS OVER STANDARD OF CARE IN PHASE III
ASTRAZENECA - ENHERTU OUTPERFORMS PLATINUM-PEMETREXED PLUS PEMBROLIZUMAB IN 1ST-LINE HER2-MUTANT NSCLC
ASTRAZENECA - ENHERTU SAFETY PROFILE IN DESTINY-LUNG04 CONSISTENT WITH KNOWN PROFILE; NO NEW SAFETY CONCERNS
ASTRAZENECA - DESTINY-LUNG04 TRIAL TO CONTINUE TO EVALUATE OVERALL SURVIVAL
Source text: ID:nRSQ8416Qa
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))